FDA Rejects Melanoma Drug RP1 Amid Leadership Controversy Under Makary

The FDA’s decision to withhold approval for Replimune’s experimental melanoma treatment RP1 has stunned oncologists and patients alike. Clinical trial data showed the drug prolonged the lives of one-third of participants, yet the agency rejected it—sparking accusations of mismanagement under current leadership.

“It was devastating news,” said Trisha Wise-Draper, a dermatologist at the University of Cincinnati who had patients enrolled in the trial. “This is life or death for maybe 2,000 patients,” added Eric Whitman, medical director of the Atlantic Health System’s oncology service.

A Wall Street Journal editorial condemned the ruling, warning it “will have a chilling effect on drug development.” While acknowledging potential concerns about RP1, industry analysts noted that Replimune had repeatedly ignored FDA recommendations to modify its trial design.

Leadership Shake-Up at the FDA

The FDA’s decision would have drawn little scrutiny before the agency’s leadership changed under Marty Makary, who became commissioner 13 months ago. Critics argue his tenure eroded the agency’s credibility, which regulates 20% of U.S. consumer spending.

“People have to speculate about the standards and processes by which the agency makes decisions,” said Steven Grossman, a regulatory consultant and former Health and Human Services official. “And that uncertainty is bad for everybody—patients, sponsors, and investors.”

Under Makary, senior FDA officials allegedly fast-tracked or suppressed drug approvals based on directives from President Donald Trump or HHS Secretary Robert F. Kennedy Jr., disregarding career scientists’ input. Makary’s combative response to criticism—accusing Replimune of “corruption” and “corporate spin”—further fueled controversy.

“I don’t work for Replimune. I work for the American people.” — Marty Makary, in a May 5 interview on CNBC

Kennedy echoed these claims during a congressional hearing, erroneously asserting that RP1 trial patients had also received chemotherapy. Makary has not responded to requests for comment.

Erosion of Trust in FDA Decision-Making

Former FDA staffers and industry experts describe a breakdown in transparency. “All the norms have been thrown out the window, so we don’t know what underlines an agency decision,” said Paul Kim, a former FDA staffer and Senate aide to Sen. Edward Kennedy who now works as a pharmaceutical consultant in Boston.

“Even when there are legitimate scientific and regulatory reasons why a drug will not be approved, we’re left guessing whether it’s legitimate grounds or just a political play.”

Melanoma by the Numbers

Melanoma remains the fifth most commonly diagnosed cancer in the U.S., with 112,000 new cases reported annually. The American Cancer Society projects 8,500 deaths from the disease this year. Replimune’s RP1 offered a glimmer of hope for patients with few remaining treatment options.